Evidence map›Paper›PMID 32742853›Full record

ArticleCureus2020

Development of Resistance Against Mefloquine Prophylaxis in Peace-Keeping Forces in the Central African Republic.

Javaria Arshad Malik, Aqib Nadeem, Zahabia Khalid, Yasser Nadeem, Sehrish Zaffar, Amer H Siddiqui

Open access · diamondAbstract read
In one paragraph

Article in Cureus, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Javaria Arshad MalikPharmacology, Combined Military Hospital (CMH) Lahore Medical College, National University of Medical Sciences (NUMS), Lahore, PAK.
Aqib NadeemAviation Medicine, Army Medical College, National University of Medical Sciences (NUMS), Islamabad, PAK.
Zahabia KhalidPharmacology, Postgraduate Medical Institute (PGMI), Lahore, PAK.
Yasser NadeemOphthalmology, Combined Military Hospital (CMH) Lahore Medical College, National University of Medical Sciences (NUMS), Lahore, PAK.
Sehrish ZaffarPharmacology, Combined Military Hospital (CMH) Lahore Medical College, National University of Medical Sciences (NUMS), Lahore, PAK.
Amer H SiddiquiPharmacology, Postgraduate Medical Institute (PGMI), Lahore, PAK.
CMH Lahore Medical College and Institute of Dentistry · PKArmy Medical College · PKCombined Military Hospital · PKNational University of Medical Sciences · PKPost Graduate Medical Institute · PK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective To record the frequency of malaria-like symptoms in patients who have been given mefloquine as chemoprophylaxis and to determine the effectiveness of antimalarials against these symptoms. Methodology It was an observational study that took place at a United Nations Level 1 hospital, Kaga-Bandoro, Central African Republic. The total duration of the study was three months. Patients presenting to the clinic with multiple symptoms despite chemoprophylaxis with mefloquine were assessed through a physical examination and screening test for malaria. Malaria treatment with a six-dose regimen of artemether (20 mg), along with lumefantrine (120 mg) two tablets BD for three days, was given after informed consent to those patients and post-treatment symptoms were observed and recorded. Results Out of 61 patients, 93% of them presented with body aches, 92% with headache, 52% with shivering, 44% with vertigo, 38% with fever, sweating, and nausea/vomiting, 18% with diarrhea, and 10% with pain in the abdomen. Conclusion It had been seen that patients presented with symptoms despite standard mefloquine prophylactic therapy, which were resolved with other antimalarial drugs. The presentation of the symptoms was also not classical.

Indexed as

anti-malarial therapymefloquine resistanceprevalence

Identifiers

PMID32742853
PMCPMC7388800
OpenAlexW3037637870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.